AIPPI weighs in on COVID waiver

The International Association for the Protection of Intellectual Property (AIPPI) has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

29 July 2021 In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.

Big Pharma

France backs COVID-19 vaccine IP waiver

14 June 2021 French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.

article

(WATCH) Lisa Ferri of Mayer Brown on the COVID-19 waiver

10 June 2021 Talks over a COVID-19 vaccine waiver ended this week at the World Trade Organization in Geneva, with an agreement to work towards a text-based response to the plan.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

AIPPI weighs in on COVID waiver

More on this story

Editor's picks

Editor's picks

More features